



In the US for 2014, opioids killed ...


- ▶ Almost 29,000 people, more than any year on record
- ▶ More than 10,500 people died from heroin overdose




MMWR / January 1, 2016 / 64(50);1378-82

Objectives – The physician will be able to:

- ▶ Identify important trends in morbidity and mortality caused by opioids
- ▶ Demonstrate the link between physician behavior and opioid addiction
- Relate the importance of using appropriate opioid writing protocols in daily practice
- Discuss the continuum between opioid prescribing and heroin addiction
- Describe several screening protocols for assessing patient depression and addiction
- ▶ Apply morphine equivalence conversion tools
- Evaluate appropriate physician prescription writing behaviors
- Create an appropriate office protocol for appropriate opioid prescription writing.




































DRUG OVERDOSE DEATHS IN PENNSYLVANIA				
Year	Number of Deaths	PA Population	Rate per 1,000	
2011	1,909	12,742,886	15.4	
2010	1,550	12,702,379	12.5	
2008	1,522	12,448,279	12.6	
2006	1,344	12,440,621	11.2	
2004	1,278	12,406,292	10.6	
2002	895	12,335,091	7.5	
2000	896	12,281,054	7.4	
1998	628	12,001,451	5.4	
1996	630	12,056,112	5.4	
1994	596	12,052,410	5.1	
1992	449	11,995,405	3.8	
1990	333	11,881,643	2.7	DDAP, 2014













High Risk Populations People taking high daily doses of opioids People who "doctor shop" People using multiple abusable substances like opioids, benzodiazepines, other CNS depressants, illicit drugs Low-income people and those living in rural areas Medicaid populations People with substance abuse or other mental health issues Medicaid populations People with substance abuse or other mental health issues HALL Ligan E. Tolkie K. Stalie M. Tang J. Kata R.P. Analytic modells to Stanffy guidents, of the for peacepting gloral values. Am J Managed Cove 2009 15(7): 877-96. HALL Ligan E. Tolkie K. Stalie M. Tang J. Kata R.P. Analytic modells to Stanffy guidents, of the for peacepting gloral values and medical values and control of the c






































It is no longer possible to simply continue previous practices.....
the associated risks of opioid diversion, overdose, and addiction demand change (now).

From the National Institute on Drug Abuse, National Institutes of Health (NIDA), Bethesda, MD and the Treatment Research Institute, Philadelphia

N Engl J Med 2016;374:1253-63. DOI: 10.1056/NEJMra1507771







2016 CDC Guideline for Prescribing Opioids for Chronic Pain


Determining When to Initiate or Continue Opioids for Chronic Pain

- 1. Nonpharmacologic therapy (including OMM) and non-opioid pharmacologic therapy are preferred for chronic pain
 - Consider opioid therapy only if expected benefits for both pain and function outweigh risks to the patient
- 2. Before starting opioid therapy for chronic pain, clinicians should establish treatment goals with all patients, including realistic goals for pain and function
 - ► Continue opioid therapy only if there is clinically meaningful improvement in pain and function

¹Adapted from 16 MMWR / March 15, 2016 / Vol. 65

2016 CDC Guideline for Prescribing Opioids for Chronic Pain (Continued)

- Discuss known risks and realistic benefits of opioid therapy before starting and periodically during opioid therapy
- 4. Prescribe immediate-release opioids instead of extended release/long-acting (ER/LA) opioids when starting opioid therapy for chronic pain
- 5. Prescribe the lowest effective dosage when starting opioids
 - ▶ Use caution when prescribing opioids at any dosage
 - Carefully reassess evidence of individual benefits and risks when increasing dosage to ≥50 morphine milligram equivalents (MME)/day
 - Avoid increasing dosage to ≥90 MME/day or carefully justify a decision to titrate dosage to ≥90 MME/day



2016 CDC Guideline for Prescribing Opioids for Chronic Pain (Continued)


Opioid Selection, Dosage, Duration, Follow-Up, and Discontinuation

- For acute pain, prescribe the lowest effective dose of immediate-release opioids and prescribe no greater quantity than needed for the expected duration
 - Three days or less will often be sufficient; more than seven days will rarely be needed
- 7. Evaluate benefits and harms with patients within 1 to 4 weeks of starting opioid therapy for chronic pain or of dose escalation.
 - ▶ If benefits do not outweigh harms of continued opioid therapy, optimize other therapies and work with patients to taper opioids to lower dosages or to taper and discontinue opioids

2016 CDC Guideline for Prescribing Opioids for Chronic Pain (Continued)

Assessing Risk and Addressing Harms of Opioid Use


- 8. Evaluate risk factors for opioid-related harm and mitigate risk
 - ▶ Offer naloxone when factors that increase risk for opioid overdose exist
 - ▶ Risk factors include history of overdose, history of substance use disorder, higher opioid dosages (≥50 MME/day), or concurrent benzodiazepine use




2016 CDC Guideline for Prescribing Opioids for Chronic Pain (Continued)

Assessing Risk and Addressing Harms of Opioid Use

- 9. Review the patient's history of controlled substance prescriptions using state database to determine misuse or abuse
 - ▶ Review data when starting opioid therapy for chronic pain and periodically during opioid therapy for chronic pain, ranging from every prescription to every 3 months
 - ▶ Identify patterns for doctor shopping or disjointed coordination of care and address them



2016 CDC Guideline for Prescribing Opioids for Chronic Pain (Continued) Assessing Risk and Addressing Harms of Opioid Use 10. Use urine drug testing before starting opioid therapy and consider repeating annually to assess misuse or abuse 11. Avoid prescribing opioid pain medication and benzodiazepines concurrently 12. Offer or arrange evidence-based MAT (usually with buprenorphine or methadone in combination with behavioral therapies) for patients with opioid use disorder



Open-source Tools Added to June 2010 Update of Opioid Dosing Guidelines Opioid Risk Tool: Screen for past and current substance abuse CAGE-AID screen for alcohol or drug abuse Patient Health Questionnaire-9 screen for depression 2-question tool for tracking pain and function Advice on urine drug testing

